NEW YORK— A companion guide to Christopher Nolan's "Interstellar" promises not only some background on one of the year's most anticipated movies but also some basic science. Publisher W.W. Norton and Company announced Wednesday that Kip Thorne's "The Science of Interstellar" will coincide with the November release of the movie.» Read More
Unlike a hurricane, tornado or snowstorm, the ends and beginning of droughts are very hard to predict.
CNBC's Meg Tirrell runs down today's top health care headlines, including a major move by President Obama to fight the Ebola virus and the latest on Enterovirus D68.
Avanir Pharma is up more than 60 percent, after the company said its drug was more effective in reducing agitation associated with Alzheimer's, compared with a placebo. CNBC's Meg Tirrell speaks to the company's CEO Keith Katkin.
Federal health experts say Novo Nordisk's diabetes drug Victoza should be approved for a new use in treating obesity.
"Big Bang" actress Mayim Bialik is a self-proclaimed science geek (she has a Ph.D.) and wants to get kids excited about math and science.
A "strong" solar flare that launched off the sun could cause some fluctuations in Earth's power grid, USA Today reports.
WASHINGTON— Earth's protective ozone layer is beginning to recover, largely because of the phase-out since the 1980 s of certain chemicals used in refrigerants and aerosol cans, a U.N. scientific panel reported Wednesday in a rare piece of good news about the health of the planet.
*Carbon dioxide levels grow at fastest rate on record. GENEVA, Sept 9- The amount of greenhouse gases in the atmosphere reached a record high in 2013 driven by a surge in the level of carbon dioxide, the World Meteorological Organization said on Tuesday, urging international action to combat climate change.
GENEVA, Sept 9- Atmospheric volumes of greenhouse hit a record in 2013 as carbon dioxide concentrations grew at the fastest rate since reliable global records began, the World Meteorological Organization said on Tuesday.
LEVEL OF CARBON DIOXIDE IN THE ATMOSPHERE INCREASED LAST YEAR AT FASTEST RATE SINCE RELIABLE GLOBAL RECORDS BEGAN THREE DECADES AGO.
Soybean planting in Brazil's leading agricultural states is only allowed after Sept. 15, following a period of three months in which the land must be left fallow to avoid the spread of disease in the tropical soil.
CNBC's Meg Tirrell speaks to Johnson & Johnson chairman, Joaquin Duato, about J&J's partnership with the National Institutes of Health to fast track its Ebola vaccine program to begin human testing by early 2015.
Discussing the new ways to monitor glucose for people with diabetes, and competition in the space, with Terry Gregg, DexCom CEO. Gregg says his business is in conversations with Apple and Samsung in regards to partnering on wearables.
CNBC's Meg Tirrell reports an American missionary doctor serving in Liberia has tested positive for Ebola.
Two major tech investors have plowed $1.5 million into Helion Energy to help it develop a technology that hasn’t worked, according to Oilprice.com.
GlaxoSmithKline is to begin human testing of an experimental Ebola vaccine. CNBC's Meg Tirrell reports the World Health Organization has released a response roadmap with the goal of stopping the spread of Ebola in 6 to 9 months.
Kite Pharma is working on a treatment which involves taking a cancer patient's own t-cells out of their body, genetically modifying them to better target cancer, and then re-administering them. Its CEO Arie Belldegrun, provides insight to the positive study with the therapy.
Aug 25- A package of bills aimed at regulating drought-parched California's stressed groundwater supplies has come under fire from agricultural interests, injecting doubt into the measures' fates in the waning days of the state's legislative session this week.
CNBC's Meg Tirrell breaks down the mega deal between Swiss pharmaceutical firm Roche and InterMune for $8.3 billion.
CNBC's Meg Tirrell speaks to Roche CEO Severin Schwan, and InterMune CEO Daniel Welch, about Roche's $8.3 billion acquisition of InterMune and the opportunity for the drug Esbriet in the U.S.